Aquavit aims to develop and commercialize its products in partnership — expanding commercial reach, accelerating delivery to the global market, and pursuing innovative product candidates at every phase of development, worldwide.
The portfolio spans a commercial device, clinical-stage programs and earlier-stage research — each with a different shape of collaboration attached to it.
Regional licensing and distribution for commercial and near-commercial assets, including the AQT-001 delivery system and the APOLLO™ compounding platform.
Joint development on botulinum toxin programs and on new indications for the microchannel delivery platform, from IND through registration.
Access to the delivery platform for a partner's own molecule — where route of administration is the constraint on an otherwise sound therapeutic.
Investigator-led studies and collaborations with academic medical centers, including work supported through the Institute for Botulinum Toxin Research — the first and only research organization dedicated to botulinum toxin research, a 501(c)(3) non-profit that Aquavit sponsors.
cGMP device and delivery-system manufacturing through Aquavit Life Sciences in South Korea, under ISO-certified quality systems.
Capital partnership on development and commercialization programs.
The company participates in the major industry and clinical meetings each year, and welcomes meeting requests in advance.
To request a meeting at any of these events, or to arrange a call, write to us and note the meeting you have in mind.
Aquavit does regulated, technical work across the Americas, Europe and Asia — drug and biologic development, device engineering, clinical operations, quality, and intellectual property.